Physician profile
Ann Glick
NPI 1609283274
$6,375.30
in general payments reported to CMS, 2019-2025
25 companies · $992 in 2025
The $992 reported for 2025 was more than what 80% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $571 · 2022: $907 · 2023: $2,696 · 2024: $1,209 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,034 · Travel and Lodging: $851 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,034.44 |
| Travel and Lodging | $850.76 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,685.24 | 2023-2025 | Neurostar Tms Therapy System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $768.31 | 2021-2025 | Caplyta |
| Abbvie INC. | $706.33 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $525.21 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $503.05 | 2022-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $375.16 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $264.59 | 2023-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $244.98 | 2021-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $146.33 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $137.17 | 2022-2025 | Auvelity |
| Corium, LLC | $136.30 | 2022-2024 | Azstarys |
| Bausch Health US, LLC | $127.63 | 2021-2023 | Wellbutrin, Aplenzin |
| Ironshore Pharmaceuticals INC. | $114.96 | 2022-2024 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $102.89 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $84.20 | 2021-2025 | Austedo Xr |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $80.96 | 2021-2022 | |
| Harmony Biosciences LLC | $55.68 | 2024-2025 | |
| Adlon Therapeutics L.P. | $53.27 | 2021 | |
| Sunovion Pharmaceuticals INC. | $51.39 | 2021 | |
| Janssen Pharmaceuticals, INC | $46.82 | 2024 | Spravato |
| Almatica Pharma LLC | $46.25 | 2021-2023 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $41.94 | 2025 | Jornay Pm |
| Livanova USA, INC. | $29.95 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Idorsia Pharmaceuticals US INC | $29.45 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $17.24 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Glick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.